DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has announced the appointment of Dr. Philippe Pultar as its senior medical advisor to bolster the development of APR-1051, a promising WEE1 inhibitor. Dr. Pultar brings a wealth of oncology experience, notably in advancing WEE1 inhibitors, having previously guided azenosertib through its clinical stages at Zentalis Pharmaceuticals.
APR-1051 is currently undergoing Phase 1 trials, targeting advanced solid tumors with specific genetic alterations. This study aims to evaluate the safety and efficacy of APR-1051, which is part of Aprea’s DNA damage response (DDR) therapeutics portfolio. The company plans to share progress updates by the end of 2024.
Dr. Pultar expressed his enthusiasm, saying, “WEE1 inhibition is a promising therapeutic approach in oncology… Aprea has a great opportunity to be a leader in this space.” His expertise is expected to enhance the clinical development and regulatory strategies for APR-1051.
Oren Gilad, Ph.D., President and CEO of Aprea, emphasized the value of Dr. Pultar’s expertise, stating, “Given the recent initiation of our Phase 1 ACESOT-1051 clinical trial… we are excited to bring on a high caliber advisor such as Dr. Pultar.”
The addition of Dr. Pultar aligns with Aprea’s strategic focus on advancing innovative cancer treatments, ensuring that patients receive the most effective therapies available.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.